CAS: 348622-88-8; (R)-5-(6-Cyclohexyl-1-(Hydroxyamino)-1-Oxohexan-3-yl)-1,2,4-Oxadiazole-3-Carboxamide

上下游产品

ethyl 5-{(1R)-1-[2-(tert-butoxy)-2-oxoethyl]-4-cyclohexylbutyl)-1,2,4-oxadiazole-3-carboxylate

📜Ethyl 5-{(1R)-1-[2-(Tert-Butoxy)-2-Oxoethyl]-4-Cyclohexylbutyl)-1,2,4-Oxadiazole-3-Carboxylate置于n-甲基吗啉,N-Trimethylsilyl-Hydroxylamin,氨,三氟乙酸,氯甲酸异丁酯体系中,用 四氢呋喃,乙醇,二氯甲烷 作为反应溶剂,化学反应生成 Uk 383367; 5-[(1R)-4-环己基-1-[2-(羟基氨基)-2-氧代乙基]丁基]-1,2,4-恶二唑-3-甲酰胺
参考文献:Procollagen C-Proteinase Inhibitors
标题:Procollagen C-Proteinase Inhibitors
摘要:它们及其盐,溶剂合物,前药等,其中取代基具有此处提及的值,是procollagen C-蛋白酶(pcp)抑制剂,并在由pcp介导的疾病中具有用途.

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.